Coordinator: Emanuele Zucca, CH
ESO has a long tradition of education in the diagnosis and treatment of lymphoma, which it has promoted through several initiatives for more than a decade.
Leukaemia and Lymphoma, advanced course
This is an intensive and interactive course organised in co-operation with the International Conference on Malignant Lymphoma (ICML). It takes place immediately before the ICML, which is held every two years in Ascona, Switzerland.
The international faculty, including ICML key note lecturers, guides participants through the complexity of the biology and the most relevant clinical problems in leukaemia and lymphoma, offering plenary lectures, practice-oriented training through case presentations, workshops in small groups and ample discussion slots. The next will take place on 10-13 June 2017.
Certificate of Competence in Lymphoma
This blended traditional seminars and distance learning curriculum of studies is organised in co-operation with University of Ulm. The programme is ECTS accredited across Europe (European Credit Transfer and Accumulation System). Unlike CME credits (Continuous Medical Education), these are recognised by Europe’s academic establishments.
The initiative provides professional development in the competence of treating lymphoma patients, opening up a new educational avenue for the School.
The programme that integrates three attendance seminars with four e-learning modules over a period of 14 months, involves a total of 405 hours of study leading to 14 ECTS points.
The first programme started in January 2013 and ended in April 2014. The second cohort started in February 2015.
Further information can be found here.
ESO Workshop at 11-ICML: “Lymphoma pretreatment assessment and response evaluation in the new millennium”
On the day before the official opening of the 11-ICML in Lugano a closed workshop was held to discuss how to improve, standardize and legitimize the current and evolving staging procedures for nodal lymphoma (Hodgkin and non-Hodgkin)and also the criteria for response to therapy in order to achieve a consensus that can last and be relevant for community physicians, investigators'-led and cooperative phase III trials and registration trials. Discussions were mainly focused on the state of the art of the currently available technologies for lymphoma staging. Several issues were identified as requiring updating, including standardization of PET methods, current indications for bone marrow biopsy, use of ‘interim’ PET-CT and the potential prognostic value of quantitative analyses using PET and CT scans. Working groups of lymphoma physicians, nuclear medicine and radiology experts were appointed to undertake a literature review and share knowledge about research in progress in order to establish the state of current knowledge, identify emerging applications, highlight key areas for research and prepare consensus guidelines.
The ICML recommendations for using PET-CT in Lymphoma have been published online and in the Journal of Clinical Oncology at http://jco.ascopubs.org/content/early/2014/08/11/JCO.2013.53.5229
As a follow up to the new guidelines on lymphoma staging and re-staging, ESO and the European School of Nuclear Medicine (ESNM) are organising a learning course on 18FDG PET-CT in Lymphoma.
ESO Workshop at 12-ICML: Identification of diffuse large B cell lymphoma subtypes: a way towards tailored treatment
The 2013 closed workshop was organized to discuss how to improve our current therapeutic approach to diffuse large B cell lymphoma (DLBCL) by exploiting the knowledge mostly recently gained on disease. Topics discussed included the state of the art of the currently available technologies, the genes and pathways affected, and the modalities to integrate all the data that can be collected and develop targeted single or combination therapies for the individual DLBCL patients.
ESO workshop at 13-ICML: Follicular Lymphoma: Recent Insights and Future Directions
(moving towards biology-driven treatments)
The main focus of the workshop is to develop an up-to-date understanding of the biology of FL and the clinical implications of new findings in the field. Specific topics discussed include, 1) a detailed understanding of the molecular correlates of disease progression and histological transformation, 2) a cataloging of the mutational spectrum at diagnosis and the clinical correlates of recurrent genetic alterations, 3) a firm understanding of clonal evolution and the role therapy has on clonal architecture over time, 4) understanding the crosstalk between the tumour cells and the microenvironment and whether this represents a targetable treatment strategy, and 5) what role does disease monitoring have in FL including the assessment of minimal residual disease (MRD).
A report is in preparation.
Dr. Fedro Peccatori is the ESO Representative in the ICML Local Organising Committee.